At last week’s ASC Annual Meeting in St. Louis, Missouri, ASP Health convened an industry symposium focused on how Rapid On-Site Evaluation (ROSE) is evolving in response to growing clinical demands and new technological capabilities. Leaders from MD Anderson Cancer Center in Houston, Crouse Health in Syracuse, and Indiana University Health in Indianapolis shared real-world perspectives on today’s ROSE workflow challenges, including increasing case complexity, staffing limitations, and the heightened need for high-quality specimens to support molecular testing.
During the session, speakers explored how automation, digital workflows, and artificial intelligence are reshaping efficiency, collaboration, and diagnostic confidence in cytology. ASP Health showcased its End-to-End ROSE Solution, designed to modernize the entire process from slide preparation through remote evaluation. The solution includes ROSE Prep™, which automates slide preparation and staining in approximately 50 seconds while preserving cellular integrity; ROSE View™, a real-time remote microscopy platform offering seamless 1x–60x magnification control with no perceptible lag; and ROSE Assist™, an AI-powered tool that provides real-time support for specimen adequacy assessment.
Clinical teams adopting these technologies are already reporting meaningful gains in speed, consistency, and workflow flexibility—particularly in multi-site, high-volume environments where access to cytology expertise can be a limiting factor. The discussions underscored a clear message: the future of ROSE is automated, digital, and AI-ready.
